Clinical Trial Update: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating BATS with low-dose IL-1 and GM-CSF in advanced pancreatic cancer (Phase 1/2) has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Carcinoma

Drugs mentioned

• BATS
• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Interleukin-1 (IL-1) inhibitor/IL-1

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-05-15